BrightView Holdings, Inc. (BV) Stock News

DBV Technologies announced the sale of approximately $50 million in American Depositary Shares (ADSs) through its At-The-Market program on Nasdaq. The company issued 18,288,220 new ordinary shares (3,657,644 ADSs) at $13.67 per ADS to RA Capital Management through Citizens JMP Securities. The issuance represents a 5.82% dilution to existing shareholders and is expected to close on August 3, 2026.

DBV Technologies announced the placement of approximately $50 million in American Depositary Shares (ADS) with RA Capital Management through its At-The-Market (ATM) program on Nasdaq. The company will issue 18.288 million new ordinary shares at $13.67 per ADS, representing a 5.82% dilution to existing shareholders. The transaction is expected to close on August 3, 2026.

Daxor Corporation announced the launch of a new outpatient Blood Volume Analysis (BVA) program at a healthcare facility in eastern Kansas through its turnkey ezBVA Lab send-out model. The service provides 98% accurate blood volume measurements within 24 hours without requiring capital equipment, enabling clinicians to optimize decongestion strategies and reduce hospital readmissions.

GBank Financial Holdings Inc. announced that its strategic partner BVNKROLL has entered into a partnership with AXES.ai to integrate BVNKROLL's embedded banking and payments platform into AXES.ai's Intelligent Management System ecosystem. BVNKROLL is a Nevada-based payments infrastructure company and joint venture between BankCard Services, LLC and BoltBetz, with GBank holding a 32.99% non-voting equity interest in BCS.

DBV Technologies has filed a new S-3ASR registration statement with the SEC to renew its at-the-market (ATM) offering program for up to $150 million in American Depositary Shares (ADSs). The company plans to use proceeds primarily for manufacturing capacity expansion, pediatric BLA submissions for peanut allergy treatment, and product development. The program was established with Citizens JMP Securities as the placement agent.

DBV Technologies announced it has completed in-depth discussions with the FDA regarding the Biologics License Application (BLA) for VIASKIN® Peanut patch for children aged 4-7 years. The FDA did not request additional data, and DBV plans to submit the BLA in Q3 2026 after incorporating FDA feedback on data organization and structuring for CMC and biostatistical elements.

DBV Technologies announced it has completed extensive discussions with the FDA regarding its Biologics License Application (BLA) for the VIASKIN® Peanut Patch in children aged 4-7 years. The FDA did not request additional data, but DBV will incorporate feedback on data organization and formatting before submitting the BLA in Q3 2026.

Aduro Clean Technologies' European subsidiary signed a non-binding memorandum of understanding with Dutch waste management company Ortessa Groep BV to evaluate the development of a feedstock logistics center supporting Aduro's first-of-a-kind (FOAK) industrial plant at Chemelot Industrial Park in the Netherlands. The collaboration aims to ensure reliable supply and proper handling of post-consumer plastic waste feedstock for the plant's chemical recycling operations using Aduro's Hydrochemolytic technology.

Aduro Clean Technologies Europe has signed a non-binding memorandum of understanding (MOU) with Ortessa Groep BV to develop feedstock logistics infrastructure supporting Aduro's First-of-a-Kind (FOAK) chemical recycling facility at Chemelot Industrial Park in the Netherlands. The collaboration will evaluate the establishment of a logistics center for collecting, managing, and supplying waste-derived feedstock materials that meet specifications for the facility's operations.

Aduro Clean Technologies Europe has signed a non-binding Memorandum of Understanding with Ortessa Groep BV to evaluate a feedstock logistics center supporting Aduro's first-of-a-kind (FOAK) chemical recycling plant at Chemelot Industrial Park in the Netherlands. The collaboration aims to ensure reliable supply of post-consumer waste materials through storage, treatment, and logistics infrastructure.

Aduro Clean Technologies Europe has signed a non-binding memorandum of understanding with Ortessa Groep BV to evaluate the establishment of a raw materials logistics center supporting Aduro's First-of-a-Kind (FOAK) industrial facility at Chemelot Industrial Park in the Netherlands. The collaboration aims to ensure safe, reliable, and efficient storage and delivery of post-consumer feedstock materials compliant with specifications, including potential use of Ortessa's sites for material preparation, quality control, and logistics management.

Aduro Clean Technologies' European subsidiary signed a non-binding memorandum of understanding with Dutch waste management company Ortessa Groep BV to develop a feedstock logistics center supporting Aduro's first-of-a-kind (FOAK) chemical recycling facility at Chemelot Industrial Park in the Netherlands. The collaboration aims to ensure reliable supply of specification-compliant post-use plastic waste materials through collection, processing, storage, and logistics solutions.

DBV Technologies announced that CEO Daniel Tassé will not participate in the previously scheduled fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, due to unavoidable travel disruption. The company will still participate in 1-on-1 investor meetings at the event in Miami, FL.

DBV Technologies announced that its management will participate in one-on-one investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 in Miami. However, CEO Daniel Tassé will not participate in the planned informal discussion due to unexpected travel disruptions.

DBV Technologies announced positive results from its Phase 3 VITESSE study showing that the VIASKIN® Peanut patch demonstrated statistically significant efficacy versus placebo in peanut-allergic children aged 4-7 years with concurrent atopic conditions including asthma, food allergies, and atopic dermatitis. The company also presented the design of its Phase 2 THRIVE study evaluating the patch in infants aged 6-12 months with peanut allergy, aiming to enable unrestricted peanut consumption after three years of treatment.

DBV Technologies announced positive Phase 3 VITESSE study results showing the VIASKIN® Peanut Patch demonstrated statistically significant efficacy versus placebo in children aged 4-7 years with peanut allergy who also have atopic comorbidities such as asthma, food allergies, or atopic dermatitis. The company also previewed its newly initiated Phase 2 THRIVE study, which will evaluate the patch's efficacy in infants aged 6-12 months with peanut allergy over three years of treatment.

DBV Technologies announced the first participant screening in the THRIVE phase 2 clinical trial evaluating the efficacy and safety of VIASKIN® Peanut patch in infants aged 6-12 months with peanut allergies. The study aims to enable ad libitum peanut consumption through early intervention immunotherapy, building on positive results from earlier trials in older children.

DBV Technologies announced the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in infants ages 6-12 months with peanut allergy. The study will assess whether the patch can enable ad lib (unrestricted) peanut consumption through epicutaneous immunotherapy (EPIT), building on positive results from earlier trials in older age groups.

Above Food Ingredients (NASDAQ:ABVE) stock plummeted 36% in after-hours trading after Nasdaq determined to delist the company's shares due to failure to file audited financial statements and its Annual Report on Form 20-F by the required deadline. Trading will be suspended at market open on June 2, 2026, with securities expected to move to the OTC market. The company is working to complete filings and may appeal the delisting decision.